[{"id":"d9e41d11-6531-42e9-b1fb-7da01cc397b6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03454451","created_at":"2021-01-18T17:02:00.296Z","updated_at":"2024-07-02T16:35:25.568Z","phase":"Phase 1","brief_title":"CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers","source_id_and_acronym":"NCT03454451","lead_sponsor":"Corvus Pharmaceuticals, Inc.","biomarkers":" MSI","pipe":"","alterations":" ","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • ciforadenant (CPI-444) • mupadolimab (CPI-006)"],"overall_status":"Completed","enrollment":" Enrollment 117","initiation":"Initiation: 04/25/2018","start_date":" 04/25/2018","primary_txt":" Primary completion: 12/28/2022","primary_completion_date":" 12/28/2022","study_txt":" Completion: 02/19/2023","study_completion_date":" 02/19/2023","last_update_posted":"2023-12-21"}]